Global $2.75 Billion Hospital Acquired Infections

Dublin, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Hospital Acquired Infections Market Analysis & Trends-Product - Forecast to 2025" report to their offering. The Global Hospital Acquired Infections Testing Market is poised to grow at a CAGR of around 19.1% over the next decade to reach approximately $2.75 billion by 2025.

Some of the prominent trends that the market is witnessing include Government Regulations to Employ an Infection Control Practitioner for Every 200 Beds, Technological Improvements in Molecular Diagnostics Field and Implementation of Patient Care and Affordable Care Act in the U.S. Reduced Infections. Based on Product the market is categorized into Specific Hospital Acquired Infections (Nosocomial) Disease Testing and Transmission Testing. Specific Hospital Acquired Infections (Nosocomial) Disease Testing is further segmented into Pseudomonas Aeruginosa, Acinetobacter Baumannii, Vancomycin-resistant Enterococcus, Clostridium Difficile, Urinary Tract Infections, Staphylococcus Aureus, Hospital-Acquired Pneumonia and Tuberculosis. Transmission Testing is further segmented into Genotypic Methods and Drug-Resistance Testing. This industry report analyzes the global markets for Hospital Acquired Infections Testing across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors. Key Topics Covered: 1 Market Outline 2 Executive Summary 3 Market Overview 3.1 Current Trends 3.1.1 Implementation of Patient Care And Affordable Care Act In The U.S. Reduced Infections 3.1.2 Technological Improvements in Molecular Diagnostics Field 3.1.3 Government Regulations to Employ An Infection Control Practitioner For Every 200 Beds 3.1.4 Recent Techlological Developments of Hospital Acquired Infections Testing 3.1.5 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 4 Hospital Acquired Infections Testing Market, By Product 4.1 Specific Hospital Acquired Infections (Nosocomial) Disease Testing 4.2 Transmission Testing 5 Hospital Acquired Infections Testing Market, By Geography 6 Key Player Activities 6.1 Mergers & Acquisitions 6.2 Partnerships, Joint Venture's, Collaborations and Agreements 6.3 Product Launch & Expansions 6.4 Other Activities 7 Leading Companies 7.1 Gen-Probe 7.2 Siemens AG 7.3 Alere 7.4 Cephei 7.5 Roche 7.6 Abbott Laboratories 7.7 Qiagen GmbH 7.8 Becton, Dickinson 7.9 Meridian Bioscience, Inc. 7.10 bioMerieux For more information about this report visit http://www.researchandmarkets.com/research/98...l_acquired

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Infectious Disease Testing